Skyrizi (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn ' s Disease in Adults

Third approved indication for Skyrizi (risankizumab-rzaa) is supported by safety and efficacy data from two induction and one maintenance clinical trials evaluating Skyrizi in moderately to severely active Crohn ' s disease, ADVANCE, MOTIVATE and...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news